Interview with Dr. Mohamed A. Al-Shaarawi, Sales Director, Pharmaceutical Solutions Industry

                                                                     Dr. Mohamed A. Al-Shaarawi, Sales Director

Give us a brief about your participation at Arab Health 2020, which was held from 27 - 30 January 2020 in Dubai, UAE. 

We were happy to meet a great number of key executives and representatives from reputed companies and visitors at the Arab Health in four days. Moreover, we feel happy to be a continuous participant in this largest healthcare exhibition & conferences in the Middle East. In fact, our participation at the show opened new opportunities for us, and following up those leads, the real challenge ahead is to turn them to customers by evaluating their interests and our capacities to meet their requirements.

Mr. Fadel Alsaad, Shareholder Relations and Corporate Manager (extreme right) and Dr. Mohamed A. Al-Shaarawi, Sales Director (2nd from right) in meeting with a business delegation at PSI Exhibit Booth in 'Arab Health 2020' in Dubai.

With your recent participation at the Arab Health 2020 what are your expectations? 

In order to widen our customer base in local as well as international markets, we are continuously enhancing our product portfolio and looking for more business opportunities beyond GCC and MENA markets. 

How significant is for your company to participate at Arab Health 2020?

Every year, our participation at Arab Health benefits in many ways. Obviously, we get opportunity to exhibit our full range of products, meet potential delegates from the healthcare industry, interact with key exhibitors for business cooperation, access newer markets and explore innovative technologies that can enable us to expand our production capacities and efficiently deliver products.

‘Connectivity for better healthcare delivery’ is the theme of Arab Health 2020. In what ways PSI can contribute its role on the delivery of healthcare?

As the leading, largest producer of a wide range of sterile IV solutions and healthcare provider in the MENA region, PSI, with its expanding product portfolio, aims to fulfil to the needs of both domestic and worldwide markets. With over 40 years, we have remained truly committed to our goals—now that, we are proud to say that PSI has served over one billion patients in the MENA region.

To provide utmost benefit for patients, we always remain accessible to meet the needs of the healthcare delivery system. We cherish our vision, which is dear to us. We are happy that while we work sincerely, we even realize that we have to work with honest passion to serve patients worldwide.

ABOUT PSI

Pharmaceutical Solutions Industry Ltd (PSI) a member of Ambah Group is the leading sterile injectable manufacturer in Middle East and Africa. Its manufacturing facilities in Saudi Arabia are GMP certified and equipped with the latest production technologies with over 40 years of proven reliable experience worldwide in contract manufacturing of parenteral solutions in plastic and glass bottles, plastic bags, as well as plastic ampoules.

In the recent past, Ambah/PSI has developed the first Ibuprofen intravenous (IV) infusion in the world (400mg/100ml). Successfully registered as Ambaprofen and Ambafen (Ibuprofen 400mg/100ml IV Infusion) through the health authorities in Germany, Spain, and Saudi Arabia, its patent has been granted by the European Patent Office (EPO patent no: 2636406) and United States Patent and Trademark Office (uspto Patent No: US 9351926 B2) for its dosage form with the approval of the European Medicines Agency (EMA).

To know more about Pharmaceutical Solutions Industry (PSI), visit the site at www.psiltd.com